How to cure dry eyes permanently: what is realistic

Dry eye is, for most people, a condition you get on top of and then keep on top of. It is not usually one you finish with. The TFOS DEWS II definition frames it as a multifactorial disease of the ocular surface in which the central problem is a loss of homeostasis of the tear film, with tear film instability, hyperosmolarity, ocular surface inflammation and damage, and, for the first time in 2017, neurosensory abnormality, named as the key mechanisms (Craig 2017). None of those is the sort of thing you switch off once and forget about.

There is a real exception, and it is worth taking seriously. Where one reversible thing is doing most of the damage, removing it can end the symptoms properly. A drying medication your prescriber is able to swap. A heat pump blowing across your desk. Contact lenses that no longer suit your eyes. A lid margin problem that has never actually been treated. Those people do sometimes finish.

So the useful question is not how to make dry eye disappear for good. It is this: which part of mine is reversible, and what does good control look like for the rest?

What controlled actually looks like

Controlled is a specific thing, not a vague hope. It means most days pass without you thinking about your eyes. It means flares still happen, on a long screen day, in wind, in a dry cabin, but they settle within a day or two rather than dragging on for a fortnight. It means a routine that takes ten or fifteen minutes a day, not an hour. And it means that when your optometrist looks again in six months, the signs have not quietly got worse.

Gone would mean no routine, no drops, no symptoms, indefinitely. That does happen, but almost always because a reversible cause was found and removed, not because the disease burned itself out.

It is worth saying plainly how thin the long-term evidence is. The DEWS II epidemiology report noted that the natural history of treated and untreated dry eye disease has been little studied and remains a priority for future research (Stapleton 2017). We can describe what tends to happen in clinic, not forecast your next decade.

The causes that are genuinely reversible

A medication. The DEWS II iatrogenic report records that a variety of systemic drugs can induce dry eye through several mechanisms, and that topical medications can cause it through allergic, toxic and immuno-inflammatory effects on the ocular surface, with preservatives such as benzalkonium chloride further aggravating it (Gomes 2017). If a drying drug is central to your picture and your prescriber has a reasonable alternative, changing it can resolve the problem rather than merely soften it. Never stop a prescribed medicine on your own to test this. Ask the person who prescribed it.

Preserved drops used many times a day. A common and slightly ironic trap: someone lubricates six or eight times daily and the surface gets steadily angrier. Switching to preservative-free often changes things within weeks.

An environmental trigger. A vent aimed at your face, a fan heater, a monitor set so high that your lids sit open wider. Cheap to test, and sometimes decisive.

Contact lenses. The same report notes that contact lens use induces, or is associated with, dry eye (Gomes 2017). A change of lens material, a shorter wearing schedule, or a genuine break can be the whole answer for some wearers.

Untreated blepharitis or a Demodex lid margin. This is the one most often missed, because people are handed lubricants for a lid disease. Treating the lid margin properly, over months rather than days, can take the symptoms away and keep them away, provided the routine continues at a maintenance level.

The parts that are managed for life

Meibomian gland dysfunction where glands have already been lost. Blocked glands can often be reopened. Glands that have dropped out on imaging are a different matter, and the evidence for regrowth is not what most people hope. We look at that question honestly in can meibomian glands grow back. Where structure has been lost, the goal shifts to protecting what remains.

Autoimmune disease. In Sjögren's syndrome and related conditions the lacrimal tissue itself is under attack, as our piece on Sjögren's syndrome and dry eye sets out. Treatment can control symptoms well, but the underlying driver stays, and the dry eye is managed alongside the systemic condition.

Age-related change. The DEWS II epidemiology meta-analysis confirmed that prevalence rises with age, and that signs increase more steeply per decade than symptoms do. Reported prevalence across studies ranged from 5 to 50 per cent, and women had a higher prevalence than men, though the difference became significant only with age (Stapleton 2017). You are managing a surface that keeps changing.

Surgical nerve change. Corneal refractive surgery and keratoplasty can cause dry eye through mechanisms intrinsic to the procedure, including corneal nerve cutting, and cataract surgery, lid surgery and cosmetic procedures are also listed as risk factors (Gomes 2017). Most post-surgical dryness improves over months. Not all of it does.

Symptoms without signs. The DEWS II classification makes room for cases where symptoms exist without demonstrable ocular surface signs, including neuropathic pain, and for non-obvious disease where signs exist without symptoms (Craig 2017). If you sit in the first group, the management is different.

Why stopping treatment usually means relapse

Almost every dry eye treatment works on the mechanism while you use it, rather than removing the mechanism. Warmth softens meibum and helps a blocked gland deliver oil, but the gland refills and can block again. A lubricant replaces what is missing for a few hours. Anti-inflammatory treatment suppresses inflammation for as long as it is on board. Lid hygiene reduces a bacterial and mite load that will rebuild if you stop.

This is not a failure of the treatments. It is what management of a long-term condition looks like, and the DEWS II management report is explicit that the sensible approach is a staged algorithm, applied step-wise according to severity, with the choice guided by whether the disease is mainly aqueous-deficient or mainly evaporative. That same review found that many available dry eye treatments lack the Level 1 evidence needed to support a firm recommendation, often because of problems with masking, randomisation, controls, selection bias or sample size (Jones 2017). Modest expectations are the correct ones.

The practical consequence is predictable. People feel better at week eight, stop everything, and are back at week fourteen. What works is a maintenance routine you can sustain, scaled up during a flare and down when things are quiet.

A realistic twelve-week plan

Before week one, get a diagnosis. Evaporative and aqueous-deficient disease are managed differently, and treating the wrong one wastes months. Start with working out which type you have, then have it confirmed properly rather than guessed.

Weeks one to four: remove what is removable, and build the routine. Ask your prescriber about any drying medication. Move to preservative-free lubricants if you are using drops often. Fix the vent, the fan and the screen height. Then build the daily routine and follow it without improvising: the sequence and timings are in the daily dry eye routine.

Weeks five to eight: keep going, and do not judge it before the end of this block. This is where most people quit. Lid margin disease and gland function change slowly, and four weeks is rarely long enough to tell whether a routine is working. Six to eight weeks of genuinely daily use is the fair trial.

Weeks nine to twelve: review and escalate if needed. Go back to your optometrist with an honest account of what you actually did. If nothing has moved, that is the point to step up the staged algorithm, which may mean prescription anti-inflammatory treatment, in-clinic procedures, or asking whether something systemic has been missed.

Some things should not wait for a review. Sudden vision loss, real pain rather than discomfort, marked light sensitivity, or a red painful eye in a contact lens wearer need to be seen the same day. And if you have an active eye infection, have had eye surgery recently, have glaucoma, or notice any change in your vision, speak to your optometrist or ophthalmologist before starting heat therapy or continuing with it.

Frequently asked questions

Can dry eyes go away permanently?

Sometimes, when one reversible cause is doing most of the work. Removing a drying medication with your prescriber's help, changing contact lenses, fixing an environmental trigger or properly treating a neglected lid margin can end symptoms for good. Where meibomian glands have been lost, or an autoimmune condition or age-related change is driving it, the realistic goal is long-term control rather than resolution.

How long should I give a new dry eye routine before deciding it has failed?

Give it six to eight weeks of consistent use before judging it, and expect very little in the first month. Gland function and lid margin disease change slowly. If you have done the routine properly for two months and nothing has shifted in either symptoms or signs, that is the point to go back and escalate rather than to keep repeating the same step.

Do I have to keep treating dry eye forever?

Usually you keep a reduced maintenance version rather than stopping entirely. Most treatments work on the mechanism while you use them, so the symptoms tend to return when the routine stops. The workable pattern is a sustainable daily habit, stepped up during a flare and eased back when things are quiet, rather than an intensive regime you abandon after a good month.

Does dry eye get worse with age?

Population data suggest it becomes more common with age. The DEWS II epidemiology meta-analysis confirmed that prevalence increases with age, with signs increasing more steeply per decade than symptoms, and reported prevalence across studies ranging from 5 to 50 per cent. That is a statement about populations, not a prediction for you, and good control is achievable at any age.

Educational information only, not medical advice. References: Craig JP, et al. Ocul Surf. 2017;15:276–283; Jones L, et al. Ocul Surf. 2017;15:575–628; Stapleton F, et al. Ocul Surf. 2017;15:334–365; Gomes JAP, et al. Ocul Surf. 2017;15:511–538.